Commercial, sales & marketing services
Bringing insights, design thinking and human ingenuity together to modernize your commercial model and drive growth.
The life sciences industry is realizing unprecedented success in bringing New Science to market, with annual launches and approvals of new medicines at all-time highs. Yet, the marketplace within which we are launching these medicines has changed significantly – from a disrupted customer model accelerated by COVID-19, to slowing pricing and margin growth due to economic constraints, the continuously evolving role of patients and the structure of healthcare systems, and the ongoing possibilities of policy and regulatory forces constantly being explored.
Given this environment, how should biopharma’s realizing the optimal economic success of New Science?
It will require a more modernized commercial model – one that is fit for today and the future.
Pharma faces the need to modernize the commercial model based on these four pressures:
COVID-19 has changed the ways customers learn about treatments and the support they need from life science companies.
Mounting public pressures to reform drug pricing and are posing greater transparency in the value chain risk to access and reimbursement.
Private pressures such as competitive entrants are propelling the decline of net price.
New customer expectations across industries, the rise in digital therapeutics and non-traditional entrants in healthcare have created new demands.
COVID-19 has disrupted the customer engagement model, but in more ways than just shifting to digital.
of patients want to use technology more for communicating with HCPs and managing their conditions.
regulatory and policy change will pose the greatest impact to margins within the next five years.
decline in Net Price Growth in the US over the next five years, significantly below the historical 4.3 percent growth.
Of patient said that the services they used – such as remote monitoring and payment support – were valuable during the pandemic.
The modern commercial model requires companies to commit to outcomes, design for impact, reach customers in new ways and digitally power operations. Life sciences companies can get there by:
Demonstrate outcomes through value-based models and access led transformation.
Designing experiences around the changing needs of patients, caregivers, and HCPs across increasingly complex care pathways. Learn more.
Optimizing market entry by empowering brand teams with therapeutic area expertise and executing flawlessly. Learn more.
Moving away from traditional marketing tactics to positioning assets to drive growth.
Introducing new engagement approaches to better support HCPs and patients. Learn more.
Playing data offense and leaning into artificial intelligence (AI) to streamline operations.
Strengthening core capabilities to promote and sustain commercial growth.
Discover how our recognition and awards distinguish us as the right partner to help you define and implement the right commercial strategy for your business.
THE FORRESTER WAVE
EVEREST GROUP PEAK SERVICES MATRIX